Targeting the $5 BILLION Soft Tissue Repair Market

Chitogenx is in the regulatory lead for regenerative products + signs MOU with major Medical Institute

Free
Message: SmallCap 60: Chitogenx (CHGX: CSE) (CHNXF: OTCQB) Completes Initial Portion of U.S Phase I/II #RotatorCuffRepair Clinical Trial

SmallCap 60: Chitogenx (CHGX: CSE) (CHNXF: OTCQB) Completes Initial Portion of U.S Phase I/II #RotatorCuffRepair Clinical Trial

posted on Dec 28, 2022 04:50PM

Share
New Message
Please login to post a reply